Skip to content

Business News

Pfizer’s BRAFTOVI ® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer ‘s BRAFTOVI combination regimen compared to 40% with investigator’s choice… Read More »Pfizer’s BRAFTOVI ® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer